Oakley C
Br Heart J. 1971;33(Suppl):Suppl:179-86. doi: 10.1136/hrt.33.suppl.179.
Semantic difficulties arise when hypertrophic obstructive cardiomyopathy is seen without obstruction and with congestive failure, and also when congestive cardiomyopathy is seen with gross hypertrophy but without heart failure. Retention of a small left ventricular cavity and a normal ejection fraction characterizes hypertrophic cardiomyopathy at all stages of the disorder. Congestive cardiomyopathy is recognized by the presence of a dilated left ventricular cavity and reduced ejection fraction regardless of the amount of hypertrophy and the presence or not of heart failure. Longevity in congestive cardiomyopathy seems to be promoted when hypertrophy is great relative to the amount of pump failure as measured by increase in cavity size. Conversely, death in hypertrophic cardiomyopathy is most likely when hypertrophy is greatest at a time when outflow tract obstruction has been replaced by inflow restriction caused by diminishing ventricular distensibility. Hypertrophy is thus beneficial and compensatory in congestive cardiomyopathy, whereas it may be the primary disorder and eventual cause of death in hypertrophic cardiomyopathy. Reasons are given for believing that hypertension may have been the original cause of left ventricular dilatation in some case of congestive cardiomyopathy in which loss of stroke output thenceforward is followed by normotension. Development of severe hypertension in these patients after recovery from a prolonged period of left ventricular failure with normotension lends weight to this hypothesis. No fault has been found in the large or small coronary arteries in either hypertrophic cardiomyopathy or congestive cardiomyopathy when they have been examined in life by selective coronary angiography, or by histological methods in biopsy or post-mortem material. Coronary blood supply may be a limiting factor in the compensatory hypertrophy of congestive cardiomyopathy, and the ability to hypertrophy may explain the better prognosis of some patients. In hypertrophic cardiomyopathy excessive metabolic demand may not be met, and inadequacy of blood flow may contribute both to sudden death and to progressive replacement fibrosis in this disease. Histochemical and ultrastructural methods have failed to show any fundamental differences between hypertrophic cardiomyopathy and congestive cardiomyopathy, whereas conventional histology permits recognition of hypertrophic cardiomyopathy and distinction both from congestive cardiomyopathy and from ;normal' secondary hypertrophy in organic aortic stenosis.
当肥厚性梗阻性心肌病无梗阻且伴有充血性心力衰竭时,以及当充血性心肌病伴有明显肥厚但无心力衰竭时,就会出现语义上的困难。在肥厚性心肌病的所有阶段,其特征是左心室腔小且射血分数正常。充血性心肌病的诊断依据是左心室腔扩大和射血分数降低,而与肥厚程度以及是否存在心力衰竭无关。当肥厚程度相对于泵衰竭程度(通过腔径增大来衡量)较大时,充血性心肌病患者的寿命似乎会延长。相反,在肥厚性心肌病中,当肥厚程度最大且流出道梗阻已被心室扩张性降低导致的流入受限所取代时,死亡的可能性最大。因此,肥厚在充血性心肌病中是有益的且具有代偿作用,而在肥厚性心肌病中它可能是原发性疾病及最终的死亡原因。有理由认为,在某些充血性心肌病病例中,高血压可能是左心室扩张的最初原因,在这些病例中,心输出量丧失后血压随后恢复正常。这些患者在经历长时间的左心室衰竭且血压正常后恢复过程中出现严重高血压,这一现象支持了这一假说。在肥厚性心肌病或充血性心肌病患者生前通过选择性冠状动脉造影,或在活检或尸检材料中通过组织学方法检查时,未发现大小冠状动脉有任何病变。冠状动脉供血可能是充血性心肌病代偿性肥厚的一个限制因素,而肥厚的能力可能解释了一些患者较好的预后。在肥厚性心肌病中,过高的代谢需求可能无法得到满足,血流不足可能导致该病的猝死和进行性替代性纤维化。组织化学和超微结构方法未能显示肥厚性心肌病和充血性心肌病之间有任何根本差异,而传统组织学能够识别肥厚性心肌病,并将其与充血性心肌病以及器质性主动脉瓣狭窄中的 “正常” 继发性肥厚区分开来。